Latest Healthcare Market News

Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.

OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.

ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.

Decidr AI Industries accelerated its commercial growth with a 71% jump in annualised exit-rate revenue to $13.6 million and bolstered its cash position to $23.4 million following a $14.2 million equity raise.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.